Retatrutide FDA approval: where it stands in September 2026 and what comes next

Photograph: editorial illustration for this article. It does not show retatrutide.

What is the FDA approval status of retatrutide?

Retatrutide is not approved. It has no brand name, no label, no approved dose and no pharmacy distribution in the United States, the European Union or anywhere else. The compound has been developed by Eli Lilly and Company (https://www.lilly.com) under the code LY3437943 since 2021, and its phase 3 program, TRIUMPH, completed its four registration trials between November 2025 and June 2026^[4][5][6][7].

The company's stated plan, in its 23 July 2026 press release, is to submit a Biologics License Application for retatrutide to the FDA in the first quarter of 2027^[1]. That is a plan, not a filing. Until an application is accepted and reviewed, the regulatory status is unchanged.

What is the path from here to an FDA decision?

1. Phase 3 read-outs, done. TRIUMPH-4 (December 2025), TRIUMPH-1 (May 2026), TRIUMPH-2 and TRIUMPH-3 (July 2026) all met their primary endpoints according to Lilly^[3][2][1].
2. BLA submission, planned Q1 2027. Because retatrutide is a peptide produced at scale, the application will include manufacturing and quality data that Lilly said it still needed to assemble after the May results.
3. FDA review. Under the standard timeline the agency has 60 days to accept the filing and then ten months to act. A priority review shortens the second part to six months, but is not automatic.
4. Decision. Approval, a complete response letter asking for more data, or a label narrower than requested. Late 2027 is the earliest plausible date for any of these.

What evidence will the application rest on?

Enrolment figures are from the ClinicalTrials.gov registry; results are from the company announcements^[2][1][3]. Detailed results, including the full safety tables the FDA will read, have been promised for medical meetings and journals but were not published at the time of writing. The phase 2 obesity trial, which is published in full, reported −24.2% at 48 weeks on 12 mg and a dose-related heart-rate increase that peaked around week 24^[9].

Why is retatrutide not approved yet?

Three reasons, none of them alarming. First, sequencing: the FDA generally wants the complete pivotal package, and TRIUMPH-2 and 3 only reported in July 2026. Second, manufacturing: a BLA for a peptide requires validated commercial-scale production data, and Lilly said publicly that it needed more time to gather quality-control data. Third, safety follow-up: the discontinuation rates for adverse events in the 12 mg arms, 11.3% in TRIUMPH-1 and up to 13.5% in TRIUMPH-3, are higher than placebo and the agency will want the full adjudicated tables^[2][1].

A separate question is what the label will say about heart rate, which rose in a dose-dependent way in phase 2. The cardiovascular outcomes trial, TRIUMPH-Outcomes, will not report until around 2029^[8], so an initial approval, if it comes, would be based on the 80-week trials and post-marketing commitments rather than on hard outcomes data.

What about Europe and other regulators?

No application has been announced to the European Medicines Agency (https://www.ema.europa.eu) or to any other regulator. Lilly's public statements concern the FDA only. Given the usual pattern for the company's incretin products, a European submission would follow the US filing rather than precede it, so European availability would come later still.

What does this mean for anyone reading about retatrutide today?

It means every product sold today under the names retatrutide, reta or GLP-3 is unapproved, whatever the label says. Research-grade material exists for laboratory use, and we explain how to tell a real certificate of analysis from a decorative one in how to read a retatrutide COA. The market for the rest is described, without endorsement, in the retatrutide grey market.